- Home
- KOPN vs PROK Comparison
KOPN vs PROK Comparison
Compare KOPN & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KOPN | PROK |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 396.8M | 416.6M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KOPN | PROK |
|---|---|---|
| Price | $3.71 | $1.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $4.69 | ★ $7.40 |
| AVG Volume (30 Days) | ★ 4.3M | 1.3M |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 103.03 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,530,311.00 | $893,000.00 |
| Revenue This Year | $50.07 | N/A |
| Revenue Next Year | $33.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 46.53 | ★ 1075.00 |
| 52 Week Low | $1.66 | $1.45 |
| 52 Week High | $6.61 | $3.55 |
Technical Indicators
Market Signals| Indicator | KOPN | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 41.79 | 40.13 |
| Support Level | $3.51 | N/A |
| Resistance Level | $4.40 | $2.59 |
| Average True Range (ATR) | 0.29 | 0.09 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 17.62 | 17.65 |
Price Performance
Historical ComparisonAbout KOPN Kopin Corporation
Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.